BofA/Merrill Lynch Downgrades Biogen (BIIB) to Neutral
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $199.15 --0%
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 7 | New: 40
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 7 | New: 40
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $143.88 yesterday.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $143.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Papa John\'s (PZZA) to Underperform, 'Management turnover increases NT uncertainty'
- CLSA Downgrades Krung Thai Bank PCL (KTB:TB) to Outperform (2)
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
